Evidence map›Paper›PMID 24681993›Full record

Trial reportPloS one2014

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Hila Haskelberg, Damien V Cordery, Janaki Amin, Anthony D Kelleher, David A Cooper, Sean Emery, STEAL Study Group

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00192634 (A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00192634 phase4completednot on this map

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.

TypeinterventionalSponsorKirby InstituteRan2005 to 2008Enrolled357ConditionsHIV InfectionsArmsEmtricitabine 200mg - Tenofovir 300mg, Abacavir 600mg - Lamivudine 300mg
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Single-cell RNAseq provides insight into altered immune cell populations in human fracture nonunions.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2023
    Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hila HaskelbergThe Kirby Institute, University of New South Wales, Sydney, Australia.
Damien V CorderyThe Kirby Institute, University of New South Wales, Sydney, Australia.
Janaki AminThe Kirby Institute, University of New South Wales, Sydney, Australia.
Anthony D KelleherThe Kirby Institute, University of New South Wales, Sydney, Australia; St Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia.
David A CooperThe Kirby Institute, University of New South Wales, Sydney, Australia; St Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia.
Sean EmeryThe Kirby Institute, University of New South Wales, Sydney, Australia.
STEAL Study Group
UNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are limited data regarding the influence of human leukocyte antigen (HLA) polymorphisms on reduced bone mineral density (BMD). We investigated the relationship between HLA supertypes and BMD in HIV-infected adults changing their existing treatment to tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine (ABC-3TC) in the STEAL study.

methodsLumbar spine and right hip BMD were measured by Dual-energy X-ray absorptiometry (DXA). HLA genotypes at the 2-digit level were classified into class I and II supertypes. Student's t-tests were used to test the association between HLA supertypes and changes in hip and spine BMD over 96 weeks for the whole cohort and stratified by randomised groups. The relationship between HLA supertypes and BMD was also assessed in the subgroup of participants that were naïve to both ABC and TDF at study entry.

resultsClass II supertypes were mainly associated with hip BMD change. Overall, compared to participants not carrying HLA-DQ3, participants expressing DQ3 had less bone loss over 96 weeks at both the hip and spine (hip: 0.003 vs. -0.006 g/cm2, 95%CI 0.002 to 0.017, p = 0.016; spine: 0.006 vs. -0.006 g/cm2, 95%CI 0.001 to 0.023, p = 0.041). In participants that were naïve to both ABC and TDF at baseline and randomised to TDF-FTC, DQ3 was significantly associated with less bone loss compared with those not carrying DQ3 (hip: 0.001 vs. -0.032 g/cm2; diff 0.033; 95%CI 0.017 to 0.049; p<0.001; spine: 0.007 vs. -0.023 g/cm2; diff 0.035; 95%CI 0.014 to 0.056; p = 0.001).

conclusionsIn this cohort of HIV-infected adults, there was an association between bone status and HLA supertypes, particularly HLA-DQ3.

trial registrationClinicaltrials.gov NCT00192634.

Indexed as

AbacavirAdenineAdultAllelesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBone DensityDeoxycytidineDideoxynucleosidesDrug CombinationsEmtricitabineFemaleHIV-1HIV InfectionsHLA-DQ AntigensHumansAbacavirabacavir, lamivudine drug combinationAdenineAnti-HIV AgentsDeoxycytidineDideoxynucleosidesDrug CombinationsEmtricitabineHLA-DQ3 antigenHLA-DQ AntigensLamivudineOrganophosphonatesTenofovir

Identifiers

PMID24681993
PMCPMC3969319
OpenAlexW2042624190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.